GC33
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic HCC
Conditions
Advanced or Metastatic HCC
Trial Timeline
Sep 1, 2008 → Oct 1, 2012
NCT ID
NCT00746317About GC33
GC33 is a phase 1 stage product being developed by Chugai Pharmaceutical for Advanced or Metastatic HCC. The current trial status is completed. This product is registered under clinical trial identifier NCT00746317. Target conditions include Advanced or Metastatic HCC.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00746317 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced or Metastatic HCC